BIOPROJET

Harmony Biosciences reports $186M net revenue for Q3 2024, surpassing $2B cumulative net revenue since WAKIX launch. Plans to submit sNDA for pitolisant in idiopathic hypersomnia in Q4 2024. Advances next-gen pitolisant-GR and pitolisant-HD programs, with IND for orexin-2 agonist on track for mid-2025. Highlights EPX-100 in rare epilepsies, with ongoing pivotal Phase 3 trials in Dravet and Lennox-Gastaut syndromes. Topline data from ZYN-002 pivotal Phase 3 RECONNECT trial in Fragile X syndrome expected mid-2025. Reiterates 2024 net product revenue guidance of $700-720M.